ArticleScience translational medicine2023

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.

Mingyue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.